Up-regulation of SNAT2 can cause complete resistance to anti-estrogen therapy and, partly, to anti-VEGF treatment, indicating that developing drugs targeting SNAT2 is a promising strategy in endocrine-resistance breast cancer. Here, SLC38A2 is linked to breast carcinoma.